US FDA delays decision on Bristol Myers-2seventy bio cancer therapy

2Seventy Bio

20/11/2023 12:18

Nov 20 (Reuters) - The U.S. Food and Drug Administration
(FDA) will not make a decision on Bristol Myers Squibb  BMY.N 
and 2seventy bio's  TSVT.O  marketing application of their blood
cancer therapy, Abecma, for earlier lines of treatment by Dec.
16.
    The health regulator will hold a meeting of external experts
before a decision, the companies said on Monday. 

 (Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj
Kalluvila)
 ((Khushi.Mandowara@thomsonreuters.com;))